Esmolol
Brevibloc, Esmolol (esmolol) is a small molecule pharmaceutical. Esmolol was first approved as Brevibloc on 1988-08-15. It is used to treat angina pectoris, heart failure, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against beta-1 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Brevibloc, Esmolol (discontinued: Brevibloc, Esmolol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Esmolol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BREVIBLOC IN PLASTIC CONTAINER | Baxter | N-019386 RX | 2001-02-16 | 1 products, RLD, RS |
| BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | Baxter | N-019386 RX | 2003-01-27 | 1 products, RLD, RS |
| BREVIBLOC | Baxter | N-019386 RX | 2003-02-25 | 1 products, RLD, RS |
| ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER | HQ Specialty Pharma | N-205703 RX | 2016-04-07 | 1 products, RLD, RS |
| ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER | HQ Specialty Pharma | N-205703 RX | 2016-04-07 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| brevibloc | New Drug Application | 2024-10-14 |
| esmolol | New Drug Application | 2017-01-18 |
| esmolol hydrochloride | ANDA | 2024-10-11 |
| esmolol hydrochloride in sodium chloride | ANDA | 2017-12-31 |
| esmolol hydrochloride in water | New Drug Application | 2024-05-31 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
103 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 3 | 4 | 7 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | 2 | 3 | 6 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | 1 | — | 1 | 4 | 6 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | — | 1 | 1 | 1 | 2 | 5 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 1 | 1 | 3 | 5 |
| Anesthesia | D000758 | — | — | — | — | 2 | 1 | 1 | 4 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | — | 1 | 2 | 4 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 1 | 2 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | 1 | — | 1 | 1 | 3 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 2 | — | 1 | — | 3 |
Show 29 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | — | A48.3 | — | 7 | 2 | — | 3 | 11 |
| Shock | D012769 | — | R57.1 | — | 7 | 2 | — | 3 | 11 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | 3 | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | 1 | — | — | 2 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | — | 2 | — | — | 2 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | 1 | 2 |
| Syndrome | D013577 | — | — | — | — | 1 | — | 1 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | 1 | — | 1 | 2 |
| Diabetic foot | D017719 | EFO_1001459 | — | 1 | 1 | 1 | — | — | 2 |
| Ulcer | D014456 | MPATH_579 | — | 1 | 1 | 1 | — | — | 2 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | — | 4 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | 1 | 1 | — | — | 2 | 3 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | 1 | — | — | 2 | 3 |
| Toxemia | D014115 | — | — | — | 1 | — | — | 2 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | 1 | — | — | — | 2 |
| Infarction | D007238 | EFO_0009463 | — | 1 | 1 | — | — | 1 | 2 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | 2 | — | — | — | 2 |
| Intratracheal intubation | D007442 | — | — | 1 | 1 | — | — | 1 | 2 |
| Postoperative cognitive complications | D000079690 | — | — | 1 | 1 | — | — | — | 1 |
| Blood pressure | D001794 | EFO_0004325 | — | — | 1 | — | — | — | 1 |
Show 18 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 4 | 4 |
| Cerebral hemorrhage | D002543 | — | — | — | — | — | — | 3 | 3 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | — | 2 | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
| Confusion | D003221 | HP_0001289 | F44.89 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Death | D003643 | PATO_0001422 | — | — | — | — | — | 1 | 1 |
| Multiple chronic conditions | D000071069 | — | — | — | — | — | — | 1 | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 1 | 1 |
Show 17 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Esmolol |
| INN | esmolol |
| Description | Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate is a methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group. It is an aromatic ether, a member of ethanolamines, a methyl ester, a secondary alcohol and a secondary amino compound. It is functionally related to a 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoic acid. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 103598-03-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL768 |
| ChEBI ID | 88206 |
| PubChem CID | 59768 |
| DrugBank | DB00187 |
| UNII ID | MDY902UXSR (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,125 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
503 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use